NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZOMIG-ZMT (zolmitriptan) by AstraZeneca is serotonin 1b receptor agonists [moa]. First approved in 2001.
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMIG-ZMT (zolmitriptan) is an oral, orally disintegrating tablet formulation of a serotonin 1b receptor agonist approved in 2001. It is indicated for acute treatment of migraine attacks in patients who experience migraine headaches. The drug works by constricting blood vessels around the brain and reducing substances in the body that cause pain, nausea, sensitivity to light and sound, and other migraine symptoms.
LOE Approaching
As LOE approaches, the brand team is likely consolidating focus on lifecycle extension strategies; sales and marketing headcount may be transitioning or rightsizing.
Mechanism of Action
Serotonin 1b Receptor Agonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Started May 2010
10 enrolled
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
Started Sep 2002
2,114 enrolled
Migraine
Career Relevance
Working on ZOMIG-ZMT in its LOE-approaching phase offers career value through experience managing competitive mature products, lifecycle extension strategy, and transition planning. This role emphasizes commercial acumen, market defense, and portfolio strategy rather than launch excitement—ideal for mid-career professionals seeking to develop deeper commercial and strategic skills.
Brand Manager
Worked on ZOMIG-ZMT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.